BIVV020 (SAR445088) n prevention and treatment of antibody-mediated rejection (AMR)

Trial Identifier: ACT17012
Sponsor: Sanofi
Start Date: June 2022
Primary Completion Date: October 2025
Study Completion Date: October 2026
Condition: Transplants - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Canada, British Columbia VANCOUVER, British Columbia, Canada, V5Z 1M9
Canada, Ontario LONDON, Ontario, Canada, N6A 5A5
Canada, Quebec MONTREAL, Quebec, Canada, H4A 3J1
CANADA, British Columbia VANCOUVER, British Columbia, CANADA, V6Z 1Y6
France BORDEAUX, France, 33076
France CRÉTEIL, France, 94010
France PARIS, France, 75010
France TOULOUSE, France, 31059
Germany BERLIN, Germany, 13353
Germany ESSEN, Germany, 45147
Germany MUNICH, Germany, 81675
Italy, Lazio ROME, Lazio, Italy, 00168
Italy, Lombardia BRESCIA, Lombardia, Italy, 25123
Italy, Milano MILAN, Milano, Italy, 20162
ITALY, Emilia-Romagna BOLOGNA, Emilia-Romagna, ITALY, 40138
Spain, Barcelona [Barcelona] BARCELONA, Barcelona [Barcelona], Spain, 08035
Spain, Madrid, Comunidad de MADRID, Madrid, Comunidad de, Spain, 28046
Spain, Madrid, Comunidad de MADRID, Madrid, Comunidad de, Spain, 28041
Sweden HUDDINGE, Sweden, 141 57
Sweden UPPSALA, Sweden, 751 85
United States, California LOS ANGELES, California, United States, 90048
United States, California LOS ANGELES, California, United States, 90095
United States, California SAN FRANCISCO, California, United States, 94143
United States, Massachusetts BOSTON, Massachusetts, United States, 02115
United States, Massachusetts BOSTON, Massachusetts, United States, 02114
United States, New York NEW YORK, New York, United States, 10016
United States, Wisconsin MADISON, Wisconsin, United States, 53792